Fundación Pública Andaluza Progreso y Salud

Quick facts

Marketed products

• Hyperbaric bupivacaine+Morphine · Anesthesia / Pain Management
  This combination uses bupivacaine (a local anesthetic) formulated as a hyperbaric solution with morphine (an opioid analgesic) to provide prolonged spinal anesthesia and analgesia.
• Hyperbaric bupivacaine+Sufentanil · Anesthesia
  Bupivacaine blocks sodium channels in nerve fibers to produce local anesthesia, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation; the hyperbaric formulation increases density for spinal distribution.
• Regular insulin added to TPN bag · Endocrinology/Metabolic
  Regular insulin lowers blood glucose by facilitating cellular glucose uptake and promoting anabolic metabolism in patients receiving total parenteral nutrition.
• Roflumilast alternated days
• Subcutaneous glargine insulin

Phase 3 pipeline

• Amchafibrin · Rare Disease
• Antipsychotic treatment · Psychiatry/Neurology
  Antipsychotic treatment works by modulating dopamine and/or serotonin neurotransmission in the brain to reduce psychotic symptoms.
• Discontinuation antipsychotic treatment · Psychiatry
  This is a clinical trial protocol studying the effects of discontinuing antipsychotic medication in patients currently treated with antipsychotics.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Fundación Pública Andaluza Progreso y Salud portfolio CI brief
• Fundación Pública Andaluza Progreso y Salud pipeline updates RSS